Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy
Hope S. Rugo, MD, FASCO, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy at ASCO 2018
Author: Annual-Meeting
Added: 06/13/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Herceptin